ALMIRALL overview

Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16 th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This year's event features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practice. The Skin Academy is a unique opportunity for collaboration, bringing together a broad range of leading experts and clinicians from...

Almirall, S.A. (ALM) , a global pharmaceutical company dedicated to medical dermatology presents five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting - including new data on tirbanibulin, a topical treatment for actinic keratosis (AK) and progress of its early-stage asset LAD191 , a high-affinity monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). These presentations provide valuable insights into patient outcomes, safety, and...

Almirall, S.A. (ALM): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250223477772/en/ Almirall HQ in Barcelona (Photo: Business Wire) Financial highlights (€ rounded million) 2024 2023 Variation Total Revenue 990.6 898.8 10.2% Net Sales 985.7 894.5 10.2% Other Income 4.9 4.3 14.0% Gross Profit 637.4 581.4 9.6% % of sales 64.7% 65.0% 10.6% Total EBITDA 192.6 174.1 Normalized Net Income 25.6 15.6 64.2% Net Income 10.1 (38.5) n.m "2024...

Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 2023-2030) and a substantial margin expansion, driven by Almirall’s focus on medical dermatology, commercial excellence, and its...

Almirall, S.A. (ALM) , a global biopharmaceutical company based in Barcelona, today announced its year to date financial results at the third quarter of 2024. Almirall continued to deliver strong sales growth in the first nine months of 2024 which were driven by the dermatology business, and especially the biologics portfolio in Europe. Net Sales increased by 7.9% YoY to a total of €727.6 MM, EBITDA was €142.2 MM (increase of 2.9% YoY) driven by higher sales growth, with a gross margin of...

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results. Financial highlights (€ rounded million) H1 2023 H1 2022 Variation Net Sales 466.1 436.6 6.8% Total EBITDA 101.3 107.6 -5.9% Net Income 12.0 27.3 -56.0% Normalized Net Income 11.6 27.6 -58.0% Summary of results Net Sales reached €466.1 MM, a +6.8% year-on-year increase boosted by the strong sales growth of the dermatology portfolio in Europe. Total EBITDA was at...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri ® (tildrakizumab) significantly improved wellbeing in patients with moderate-to-severe plaque psoriasis achieving a wellbeing status similar to the general population 1 after 16 weeks, which was maintained up to week 28 ¡Error! Marcador no definido. . These first results of the POSITIVE study were presented in a poster at the 25 th World Congress of Dermatology, held in...

Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of people living with psoriatic disease believe that it negatively affects their daily activities, causing a heavy physical, emotional and social burden that affects their mental health 1 and wellbeing 2 . Despite its high prevalence - approximately 1.52% of the UK population (1.01 million people estimated)...